Sign In
Buy PCRX
$22.32
+0.0700 (+0.315%)
At Close: Jun 03, 2026
Here's What Key Metrics Tell Us About Pacira (PCRX) Q1 Earnings
06:31pm, Tuesday, 07'th May 2024
While the top- and bottom-line numbers for Pacira (PCRX) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to
Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program
04:00pm, Tuesday, 07'th May 2024
-- Conference call today at 4:30 p.m. ET -- TAMPA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management a
Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
08:00am, Tuesday, 07'th May 2024
TAMPA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2024 RBC Capital Markets Global He
Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024
08:00am, Tuesday, 30'th Apr 2024
TAMPA, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results after the close of the U.S. markets on Tu
Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
08:00am, Tuesday, 02'nd Apr 2024
TAMPA, Fla., April 02, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 23rd Annual Needham Virtual Heal
Pacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag
09:26am, Thursday, 14'th Mar 2024
Pacira (PCRX) receives the FDA's RMAT designation for its gene-therapy product candidate, PCRX-201, which is currently being developed in an early-stage study to treat osteoarthritis of the knee.
-- PCRX-201 is the first gene therapy product candidate to receive RMAT designation for osteoarthritis -- -- Designation supported by encouraging preliminary data from 72-patient Phase 1 study --
Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference
08:00am, Wednesday, 06'th Mar 2024
TAMPA, Fla., March 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays 26th Annual Global Heal
Pacira (PCRX) Q4 Earnings Match, Exparel Sales Drive Revenues
07:06am, Friday, 01'st Mar 2024
Pacira (PCRX) reports fourth-quarter 2023 results, wherein earnings match and revenues beat estimates, driven by strong Exparel sales.
Here's What Key Metrics Tell Us About Pacira (PCRX) Q4 Earnings
11:01am, Thursday, 29'th Feb 2024
The headline numbers for Pacira (PCRX) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estima
Pacira (PCRX) Matches Q4 Earnings Estimates
10:16am, Thursday, 29'th Feb 2024
Pacira (PCRX) came out with quarterly earnings of $0.89 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.80 per share a year ago.
Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results
08:00am, Thursday, 29'th Feb 2024
— Record revenues of $675 million in 2023 — — Full-year GAAP net income of $42 million and adjusted EBITDA of $214 million — — EXPAREL surpasses the 14 million patient mark — — Conferenc
Countdown to Pacira (PCRX) Q4 Earnings: Wall Street Forecasts for Key Metrics
10:20am, Monday, 26'th Feb 2024
Evaluate the expected performance of Pacira (PCRX) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics
Pacira to Report 2023 Financial Results on Thursday February 29, 2024
08:00am, Thursday, 22'nd Feb 2024
TAMPA, Fla., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2023 financial results before t
Pacira (PCRX) Earnings Expected to Grow: What to Know Ahead of Q4 Release
11:06am, Tuesday, 20'th Feb 2024
Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
